Compare · KLRA vs NVO
KLRA vs NVO
Side-by-side comparison of Kailera Therapeutics Inc. (KLRA) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KLRA and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 114.4x KLRA ($1.52B).
- NVO has been more active in the news (3 items in the past 4 weeks vs 2 for KLRA).
- NVO has more recent analyst coverage (25 ratings vs 6 for KLRA).
- Company
- Kailera Therapeutics Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $1.52B
- $173.66B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- News (4w)
- 2
- 3
- Recent ratings
- 6
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest KLRA
- Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting
- Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection
- Kailera Therapeutics to Participate in September Investor Conferences
- SEC Form 4 filed by Chief Technology Officer Nicholson Nur
- SEC Form 3 filed by new insider Nicholson Nur
- SEC Form SCHEDULE 13G filed by Kailera Therapeutics Inc.
- SEC Form 10-Q filed by Kailera Therapeutics Inc.
- Kailera Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates
- Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank